ELISA/assay

Bovine Endothelin 1 ELISA Kit

MBS737049

48-Strip-Wells

470 USD

ELISA Kit

Bovine Endothelin 1 ELISA Kit

Endothelin 1

endothelin-1; Endothelin-1; endothelin-1; preproendothelin-1; endothelin 1; Preproendothelin-1; PPET1

EDN1

EDN1; EDN1; ET1; QME; PPET1; ARCND3; HDLCQ7; PPET1; ET-1

EDN1_HUMAN

Bovine

This assay has high sensitivity and excellent specificity for detection of EDN-1. No significant cross-reactivity or interference between EDN-1 and analogues was observed. NOTE: Limited by current skills and knowledge, it is impossible for us to complete the cross-reactivity detection between EDN-1 and all the analogues, therefore, cross reaction may still exist in some cases.

Store all reagents at 2-8 degree C.

Samples: Serum, plasma, Cell Culture Supernatants, body fluid and tissue homogenate. Assay Type: Competitive. Sensitivity: 0.1 ng/mL.

Intended Uses: This EDN-1 ELISA kit is a 1.5 hour solid-phase ELISA designed for the quantitative determination of Bovine EDN-1. This ELISA kit for research use only, not for therapeutic or diagnostic applications!

Signal Transduction

Principle of the assay: EDN-1 ELISA kit applies the competitive enzyme immunoassay technique utilizing a monoclonal anti-EDN-1 antibody and an EDN-1-HRP conjugate. The assay sample and buffer are incubated together with EDN-1-HRP conjugate in pre-coated plate for one hour. After the incubation period, the wells are decanted and washed five times. The wells are then incubated with a substrate for HRP enzyme. The product of the enzyme-substrate reaction forms a blue colored complex. Finally, a stop solution is added to stop the reaction, which will then turn the solution yellow. The intensity of color is measured spectrophotometrically at 450nm in a microplate reader. The intensity of the color is inversely proportional to the EDN-1 concentration since EDN-1 from samples and EDN-1-HRP conjugate compete for the anti-EDN-1 antibody binding site. Since the number of sites is limited, as more sites are occupied by EDN-1 from the sample, fewer sites are left to bind EDN-1-HRP conjugate. A standard curve is plotted relating the intensity of the color (O.D.) to the concentration of standards. The EDN-1 concentration in each sample is interpolated from this standard curve.

556203

AAA52339.1

24,425 Da

Class A/1 (Rhodopsin-like Receptors) Pathway (106357); EGFR-dependent Endothelin Signaling Events Pathway (138037); Endothelin Pathway (672453); Endothelins Pathway (137958); G Alpha (q) Signalling Events Pathway (106043); GPCR Downstream Signaling Pathway (119548); GPCR Ligand Binding Pathway (161020); Gastrin-CREB Signalling Pathway Via PKC And MAPK (645295); HIF-1 Signaling Pathway (695200); HIF-1-alpha Transcription Factor Network Pathway (138045)

The protein encoded by this gene is proteolytically processed to release a secreted peptide termed endothelin 1. This peptide is a potent vasoconstrictor and is produced by vascular endothelial cells. Endothelin 1 also can affect the central nervous system. Two transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Nov 2009]

EDN1: Endothelins are endothelium-derived vasoconstrictor peptides. Belongs to the endothelin/sarafotoxin family. Protein type: Secreted; Secreted, signal peptide. Chromosomal Location of Human Ortholog: 6p24.1. Cellular Component: extracellular space; cytoplasm; extracellular region. Molecular Function: protein binding; hormone activity; endothelin B receptor binding; cytokine activity; endothelin A receptor binding. Biological Process: response to nicotine; positive regulation of JNK activity; elevation of cytosolic calcium ion concentration during G-protein signaling, coupled to IP3 second messenger (phospholipase C activating); positive regulation of nitric oxide biosynthetic process; regulation of systemic arterial blood pressure by endothelin; heart development; response to lipopolysaccharide; middle ear morphogenesis; prostaglandin biosynthetic process; sensory perception of pain; positive regulation of MAP kinase activity; negative regulation of cAMP biosynthetic process; elevation of cytosolic calcium ion concentration; cell surface receptor linked signal transduction; cell-cell signaling; negative regulation of nitric-oxide synthase biosynthetic process; protein kinase C activation; cell growth; neutrophil chemotaxis; rhythmic excitation; positive regulation of mitosis; negative regulation of blood coagulation; positive regulation of heart rate; respiratory gaseous exchange; response to testosterone stimulus; response to amino acid stimulus; peptide hormone secretion; leukocyte activation; patterning of blood vessels; membrane depolarization; protein kinase C deactivation; regulation of vasoconstriction; positive regulation of transcription from RNA polymerase II promoter; response to activity; superoxide release; positive regulation of odontogenesis; epithelial fluid transport; phosphoinositide 3-kinase cascade; G-protein signaling, phospholipase D activating pathway; positive regulation of cell size; neural crest cell development; positive regulation of smooth muscle cell proliferation; negative regulation of hormone secretion; negative regulation of cellular protein metabolic process; negative regulation of transcription from RNA polymerase II promoter; glucose transport; vein smooth muscle contraction; histamine secretion; nitric oxide transport; positive regulation of cell proliferation; regulation of pH; positive regulation of smooth muscle contraction; artery smooth muscle contraction; vasoconstriction; inositol phosphate-mediated signaling; in utero embryonic development; positive regulation of hormone secretion; calcium-mediated signaling; multicellular organismal aging; body fluid secretion; G-protein coupled receptor protein signaling pathway; dorsal/ventral pattern formation; response to ozone; cartilage development; positive regulation of prostaglandin secretion; maternal process involved in parturition; regulation of sensory perception of pain; positive regulation of cell migration. Disease: Question Mark Ears, Isolated; Auriculocondylar Syndrome 3

48-Strip-Wells

470 USD

96-Strip-Wells

675